PRXIQ yields 2000000.00% · JNJ yields 2.13%● Live data
📍 PRXIQ pulled ahead of the other in Year 1
Combined, PRXIQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PRXIQ + JNJ for your $10,000?
Premier Exhibitions, Inc., together with its subsidiaries, engages in presenting museum-quality touring exhibitions to public worldwide. It operates through two segments, Exhibition Management and RMS Titanic. It develops, deploys, operates, and presents exhibition products in exhibition centers, museums, and non-traditional venues. The company operates and manages various exhibitions, such as 'Titanic: The Artifact Exhibition' that features the artifacts recovered from the wreck site; Titanic: The Experience, a Titanic-themed exhibition; and 'Bodies...The Exhibition' and 'Bodies Revealed', which display multiple human anatomy sets that contain a collection of whole human body specimens, and single human organs and body parts. It also operates and manages 'Pompeii: One Day in Pompeii', which features the artifacts recovered from the debris of the city of Pompeii; 'Real Pirates' that tells the story of the Whydah, the first authenticated pirate shipwreck in U.S. waters, and the stories of the people whose lives converged on the vessel; and 'The Discovery of King Tut', an exhibition based on King Tutankhamun. In addition, the company sells merchandise, such as apparel, posters, gifts, and jewelry related to its shows over the Internet; publishes exhibition catalogs; and provides ancillary services, such as audio tours, as well as sells visitor exhibition themed photographs at its exhibition gift shops. Premier Exhibitions, Inc. was founded in 1987 and is based in Peachtree Corners, Georgia.
Full PRXIQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.